Effects of levomilnacipran: A Synthesis of Findings from 29 Studies

  1. Home
  2. Effects of levomilnacipran
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of levomilnacipran: A Synthesis of Findings from 29 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of levomilnacipran: A Synthesis of Findings from 29 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Levomilnacipran, a serotonin-norepinephrine reuptake inhibitor (SNRI), has been shown to be effective in treating major depressive disorder (MDD). 20 In several clinical trials, levomilnacipran was more effective than placebo in reducing depressive symptoms. 23 29 Levomilnacipran has also been shown to improve functional impairment in patients with MDD. 19 Levomilnacipran is more potent at inhibiting norepinephrine reuptake than serotonin reuptake, which may contribute to its effectiveness in treating symptoms of MDD related to motivation and energy. 3 The study also found that levomilnacipran improved cognitive function in patients with MDD and reduced their self-reported functional impairment. 2 Furthermore, levomilnacipran has been shown to reduce fatigue in patients with MDD. 5

Benefits and Risks

Benefit Summary

Levomilnacipran has been shown to be effective in reducing depressive symptoms, improving functional impairment, improving cognitive function, and reducing fatigue in patients with MDD. 20 23 29 19 3 2 5

Risk Summary

Levomilnacipran is generally well tolerated, but it can cause side effects such as nausea, sweating, constipation, tachycardia, palpitations, erectile dysfunction, and ejaculatory disorder. 20 8 Some patients may also experience hypertension or orthostatic hypotension. 20

Comparison Between Studies

Commonalities

Multiple studies have shown that levomilnacipran is effective in reducing depressive symptoms compared to placebo. 20 8 23 29 Additionally, several studies have shown that levomilnacipran is effective in improving functional impairment in patients with MDD. 19

Differences

There are some differences between studies in terms of the effectiveness and side effects of levomilnacipran. 20 8

Consistency and Contradictions in Results

Multiple studies have shown that levomilnacipran is effective in treating depressive symptoms, but there are some differences between studies in terms of effectiveness and side effects. 20 8 Further research is needed to evaluate the long-term effectiveness and safety of levomilnacipran.

Notes on Applying Research to Real Life

While levomilnacipran has been shown to be effective in treating depression, it is important to remember that it can also cause side effects. 20 8 If you are considering taking levomilnacipran, it is important to talk to your doctor about your symptoms and any potential risks.

Limitations of Current Research

The research on levomilnacipran is still limited. In particular, there is a lack of research on the long-term effectiveness and safety of the drug. 20 There is also a lack of research comparing the effectiveness of levomilnacipran to other antidepressants.

Future Research Directions

Future research should focus on evaluating the long-term effectiveness and safety of levomilnacipran, as well as comparing its effectiveness to other antidepressants. It is also important to investigate whether levomilnacipran is appropriate for specific patient populations, such as older adults or pregnant women.

Conclusion

Levomilnacipran has been shown to be effective in treating depressive symptoms in multiple clinical trials. 20 8 23 29 However, research on levomilnacipran is still limited. If you are considering taking levomilnacipran, it is important to talk to your doctor to understand your symptoms and any potential risks.

Literature analysis of 29 papers
Positive Content
29
Neutral Content
0
Negative Content
0
Article Type
11
0
1
11
29
2.

Effects of levomilnacipran extended-release on major depressive disorder patients with cognitive impairments: post-hoc analysis of a phase III study.

Author: WesnesKeith A, GommollCarl, ChenChangzheng, SambunarisAngelo, McIntyreRoger S, HarveyPhilip D

Improved cognition
Reduced functional impairment

This study investigated the effects of levomilnacipran extended-release (ER) on cognition, depression symptoms, and psychosocial functioning in adults with major depressive disorder. Levomilnacipran ER improved both cognitive function and depression symptoms, leading to significant reductions in self-reported functional impairment.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

3.

Effects of levomilnacipran extended-release on motivation/energy and functioning in adults with major depressive disorder.

Author: ThaseMichael E, GommollCarl, ChenChangzheng, KramerKenneth, SambunarisAngelo

Improved motivation
Reduced functional impairment

Levomilnacipran extended-release (ER) has been shown to improve motivation/energy in patients with major depressive disorder (MDD). This study found that improvements in functional impairment were considerably mediated by improvements in motivation/energy, particularly in patients with lower motivation/energy at baseline.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

4.

The effects of levomilnacipran ER in adult patients with first-episode, highly recurrent, or chronic MDD.

Author: KornsteinSusan G, GommollCarl, ChenChangzheng, KramerKenneth

Levomilnacipran ER
MDD treatment

This study evaluated the efficacy of levomilnacipran extended-release (ER) in patients with different major depressive disorder (MDD) episode histories. Post hoc analyses from five studies showed consistent efficacy of levomilnacipran ER across varying MDD episode histories.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

5.

Effects of levomilnacipran ER on fatigue symptoms associated with major depressive disorder.

Author: FreemanMarlene P, FavaMaurizio, GommollCarl, ChenChangzheng, GreenbergWilliam M, RuthAdam

Depression treatment
Fatigue reduction

This study evaluated the effects of levomilnacipran extended-release (ER) on depression-related fatigue in adults with major depressive disorder. Levomilnacipran ER treatment was effective in reducing depression-related fatigue and was associated with remission of fatigue symptoms.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

6.

The efficacy of levomilnacipran ER across symptoms of major depressive disorder: a post hoc analysis of 5 randomized, double-blind, placebo-controlled trials.

Author: McIntyreRoger S, GommollCarl, ChenChangzheng, RuthAdam

Levomilnacipran ER effective

Levomilnacipran ER treatment improved across a range of depression symptoms and symptom domains in adult patients with major depressive disorder. Patients receiving levomilnacipran ER showed greater mean improvements on all Montgomery-Åsberg Depression Rating Scale (MADRS) items except Reduced Appetite.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

7.

LEVOMILNACIPRAN--A SUCCESSOR OF MILNACIPRAN WITH A HIGHER NORADRENERGIC SELECTIVITY.

Author: ZadkaŁukasz, DziwotaEwelina, OlajossyMarcin

Efficacy
Improved safety

Levomilnacipran, a selective serotonin-norepinephrine reuptake inhibitor (SNRI) with high noradrenergic selectivity, is effective in treating depression and is safer than its racemate.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

9.

The serotonergic system in the neurobiology of depression: Relevance for novel antidepressants.

Author: KöhlerStephan, CierpinskyKatharina, KronenbergGolo, AdliMazda

Improved cognition
Reduced anxiety
Side effects

This review explores the role of serotonin receptors in depression and the potential of new antidepressants that target these receptors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

10.

Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition.

Author: ChenLaishun, GreenbergWilliam M, GommollCarl, O'ConnorJoann, ZukinStephen R, PericlouAntonia, GhahramaniParviz

MDD treatment

This study characterized the pharmacokinetic (PK) parameters of levomilnacipran in healthy subjects and in patients with major depressive disorder (MDD).

Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

11.

Effect of renal impairment on the pharmacokinetics of levomilnacipran following a single oral dose of levomilnacipran extended-release capsule in humans.

Author: ChenLaishun, GreenbergWilliam M, Brand-SchieberElimor, WangsaJulie, PericlouAntonia, GhahramaniParviz

Well tolerated
Increased plasma levels
Prolonged half-life

Renal impairment was associated with increased plasma levels and prolonged half-life of levomilnacipran. No dose adjustment is required for mild impairment, but the maximum daily dose should not exceed 80 mg for moderate impairment and 40 mg for severe impairment.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

12.

Vortioxetine (Brintellix®) and levomilnacipran (Fetzima®): the two newest additions to the antidepressant formulary.

Author: RomanMarian W, WilkinsonShannon M

Depression treatment

The US Food and Drug Administration approved two new antidepressant formulations, vortioxetine (Brintellix(®)) and levomilnacipran (Fetzima(®)) in late 2013.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

13.

Levomilnacipran extended-release: a review of its use in adult patients with major depressive disorder.

Author: ScottLesley J

Depression treatment

This article summarizes the clinical use of oral levomilnacipran extended-release (ER) in adults with major depressive disorder (MDD). Levomilnacipran ER is a serotonin norepinephrine reuptake inhibitor that has been shown to be effective and generally well-tolerated in treating MDD.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

14.

A review of the clinical efficacy, safety and tolerability of the antidepressants vilazodone, levomilnacipran and vortioxetine.

Author: DeardorffWilliam James, GrossbergGeorge T

Antidepressant effect
Adverse events

Major depressive disorder (MDD) is a leading cause of disability and is characterized by reduced quality of life and altered functioning. Current pharmaceutical treatment options are limited in their success due to modest effects and adverse events that often lead to discontinuation. One current trend in antidepressant development is to combine inhibition of the serotonin transporter with other pharmacological targets, including the norepinephrine transporter or different serotonin receptors.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

15.

Risk of QT/QTc prolongation among newer non-SSRI antidepressants.

Author: JasiakNatalia M, BostwickJolene R

Low QT prolongation risk
QT prolongation in overdose

The majority of newer non-SSRI antidepressants showed a low risk of QT prolongation at therapeutic doses. The highest risk for QT prolongation is seen in overdose situations with venlafaxine and bupropion.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Efficacy of levomilnacipran extended-release in major depressive disorder: pooled analysis of 5 double-blind, placebo-controlled trials.

Author: MontgomeryStuart A, GommollCarl P, ChenChangzheng, GreenbergWilliam M

Improved depression symptoms
Increased remission rate
Increased response rate

Levomilnacipran extended-release (ER) is efficacious for major depressive disorder (MDD) across a wide range of patients. In pooled data from 5 phase II/III studies, levomilnacipran ER showed significant improvements in MADRS scores, response rates, and remission rates compared to placebo. These effects were consistent across subgroups based on sex, age, MDD duration, and symptom severity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

18.

Effect of hepatic impairment on the pharmacokinetics of levomilnacipran following a single oral dose of a levomilnacipran extended-release capsule in human participants.

Author: ChenLaishun, BoinpallyRamesh, GreenbergWilliam M, WangsaJulie, PericlouAntonia, GhahramaniParviz

Levomilnacipran extended-release (ER) 40mg is generally well-tolerated in adults with varying degrees of hepatic impairment. Dose adjustment is not necessary in adults with impaired liver function.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Efficacy of levomilnacipran extended-release in improving functional impairment associated with major depressive disorder: pooled analyses of five double-blind, placebo-controlled trials.

Author: SambunarisAngelo, GommollCarl, ChenChangzheng, GreenbergWilliam M

Functional remission
Improved function

Levomilnacipran extended-release (ER) was more effective than placebo in improving functional impairment in patients with major depressive disorder (MDD). The improvement in functional outcomes was observed across various subgroups, including both sexes and different age groups, regardless of baseline depression severity and functional impairment levels.

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

20.

Levomilnacipran: a newly approved drug for treatment of major depressive disorder.

Author: MagoRajnish, MahajanRajeev, ThaseMichael E

Treat major depressive disorder
Constipation
Ejaculation disorder
Erectile dysfunction
Hyperhidrosis
Hypertension
Nausea
Orthostatic hypotension
Palpitations
Tachycardia
Vomiting

Levomilnacipran, a new serotonin and norepinephrine reuptake inhibitor (SNRI), is effective in treating major depressive disorder in the short-term. While it shows promise, further research is needed to compare its efficacy to other antidepressants and to assess its long-term effectiveness.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

21.

Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder.

Author: SaraceniMegan M, VenciJineane V, GandhiMona A

Major depressive disorder treatment

Levomilnacipran ER, a serotonin-norepinephrine reuptake inhibitor, is generally well tolerated and effective for treating major depressive disorder. It is a potent norepinephrine reuptake inhibitor, a potential benefit compared to other antidepressants.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

22.

A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder.

Author: SambunarisAngelo, BoseAnjana, GommollCarl P, ChenChangzheng, GreenbergWilliam M, SheehanDavid V

Improved depression symptoms
Constipation
Dizziness
Nausea

Levomilnacipran extended release (ER) is a serotonin and norepinephrine reuptake inhibitor that showed significant improvement in symptoms of major depressive disorder compared to placebo.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

23.

The efficacy of extended-release levomilnacipran in moderate to severe major depressive disorder: secondary and post-hoc analyses from a randomized, double-blind, placebo-controlled study.

Author: MontgomeryStuart A, MansuyLucilla, RuthAdam C, LiDayong, GommollCarl

Functional improvement
Improved depression symptoms

Levomilnacipran extended release (ER) is a serotonin and norepinephrine reuptake inhibitor that showed significant improvement in symptoms and function in patients with major depressive disorder compared to placebo.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study.

Author: BakishDavid, BoseAnjana, GommollCarl, ChenChangzheng, NunezRene, GreenbergWilliam M, LiebowitzMichael, KhanArif

Effective for MDD
Adverse events

A 10-week, double-blind, placebo-controlled study of levomilnacipran ER in patients with major depressive disorder found that levomilnacipran ER at doses of 40 mg/day and 80 mg/day demonstrated efficacy in improving both symptomatic and functional measures of MDD compared to placebo. Levomilnacipran ER was generally well tolerated, although more patients in the treatment group prematurely exited the study due to adverse events.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

25.

Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

Author: CitromeL

Effective for MDD
Favorable weight-gain profile
Adverse events

Levomilnacipran is effective for the treatment of major depressive disorder (MDD). The number needed to treat for response was 9 and the number needed to treat for remission was 14. The number needed to harm for discontinuation due to adverse events was 19.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Language : English

26.

Levomilnacipran extended release: first global approval.

Author: HairPhilip, CameronFiona, Garnock-JonesKarly P

MDD treatment
Stroke recovery improvement

This article summarizes the development of levomilnacipran extended release (ER), an enantiomer of milnacipran, for the treatment of major depressive disorder (MDD). It highlights the milestones leading to the drug's approval for this indication.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

27.

Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study.

Author: MagoRajnish, ForeroGiovanna, GreenbergWilliam M, GommollCarl, ChenChangzheng

Safe and tolerable
Adverse events

Levomilnacipran extended-release (ER) was generally well-tolerated in a 48-week open-label extension study. The most common adverse events were headache (22%) and nausea (16%). No clinically meaningful changes occurred in mean liver enzyme, metabolic, hematologic, urinalysis, or serum values. Mean increases were noted for pulse rate (9.1 bpm), and supine systolic (3.9 mmHg) and diastolic (3.3 mmHg) blood pressure.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

28.

Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.

Author: MontgomeryStuart A, MansuyLucilla, RuthAdam, BoseAnjana, LiHua, LiDayong

Levomilnacipran
MDD treatment
Adverse events

A 10-week, randomized, double-blind, placebo-controlled trial of 276 patients with major depressive disorder (MDD) found that levomilnacipran sustained release (SR) was significantly superior to placebo on all measures of depression severity, response, and remission. Levomilnacipran SR was generally safe and well tolerated.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

29.

Efficacy and safety of levomilnacipran sustained release 40 mg, 80 mg, or 120 mg in major depressive disorder: a phase 3, randomized, double-blind, placebo-controlled study.

Author: AsnisGregory M, BoseAnjana, GommollCarl P, ChenChangzheng, GreenbergWilliam M

Improved depressive symptoms
Common side effects

Levomilnacipran sustained release demonstrated significant improvement in depressive symptoms and functioning relative to placebo. It was generally well tolerated.

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.